Amlie J P, Landmark K
Acta Pharmacol Toxicol (Copenh). 1978 Apr;42(4):287-91. doi: 10.1111/j.1600-0773.1978.tb02203.x.
The effect of nifedipine (BAY 1040), a calcium-antagonistic inhibitor of the electromechanical coupling process was tested on atrioventricular conduction and refractoriness of the dog heart in situ by means of His-bundle electrography and programmed electrical stimulation. The animals were anaesthetized with sodium pentobarbital. As the basic effects of the compound can be altered by release of catecholamines from sympathetic nerves of heart and vessels, the dogs were pretreated with acebutolol, a beta-adrenergic receptor blocking agent, which decreased heart rate and prolonged atrioventricular conduction and refractoriness. Nifedipine 1,6 and particularly 30 microgram/kg body weight increased the heart rate and decreased atrioventricular conduction time during atrial pacing, whereas atrioventricular conduction time during sinus rhythm and atrioventricular refractoriness were only affected by nifedipine 30 microgram/kg. In this respect, nifedipine differs distinctly from another calcium antagonistic compound, verapamil.
硝苯地平(BAY 1040)是一种钙拮抗抑制剂,可抑制机电耦联过程。通过希氏束电图和程控电刺激,对狗原位心脏的房室传导和不应期进行了测试。动物用戊巴比妥钠麻醉。由于该化合物的基本作用可因心脏和血管交感神经释放儿茶酚胺而改变,因此给狗预先使用了醋丁洛尔,一种β肾上腺素能受体阻滞剂,它可降低心率并延长房室传导和不应期。体重1、6微克/千克,尤其是30微克/千克的硝苯地平可使心房起搏时心率增加,并缩短房室传导时间,而窦性心律时的房室传导时间和房室不应期仅受30微克/千克硝苯地平的影响。在这方面,硝苯地平与另一种钙拮抗化合物维拉帕米明显不同。